Entrada TherapeuticsTRDA
TRDA
About: Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Employees: 177
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
156% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 9
111% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 19
110% more call options, than puts
Call options by funds: $551K | Put options by funds: $262K
17% more funds holding
Funds holding: 83 [Q2] → 97 (+14) [Q3]
14% more capital invested
Capital invested by funds: $424M [Q2] → $481M (+$57.6M) [Q3]
0.88% more ownership
Funds ownership: 80.04% [Q2] → 80.92% (+0.88%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
14%
upside
Avg. target
$26
46%
upside
High target
$29
65%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Roth MKM Boobalan Pachaiyappan 0% 1-year accuracy 0 / 5 met price target | 65%upside $29 | Buy Initiated | 5 Dec 2024 |
Oppenheimer Francois Brisebois 43% 1-year accuracy 15 / 35 met price target | 59%upside $28 | Outperform Maintained | 6 Nov 2024 |
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 118 / 313 met price target | 14%upside $20 | Buy Maintained | 6 Nov 2024 |
Financial journalist opinion
Based on 3 articles about TRDA published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P.
Positive
Zacks Investment Research
2 weeks ago
Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why
Entrada Therapeutics (TRDA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Positive
Zacks Investment Research
4 weeks ago
Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why
Entrada Therapeutics (TRDA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Negative
Zacks Investment Research
1 month ago
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to earnings of $1.02 per share a year ago.
Positive
Zacks Investment Research
1 month ago
Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going
Entrada Therapeutics (TRDA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Neutral
GlobeNewsWire
2 months ago
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
– Additional positive data from the Company's completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a Phase 2 clinical trial – – Preclinical data presented for the first time, showing exon skipping and dystrophin production for ENTR-601-45, supports the planned Q4 2024 regulatory filings for a global direct-to-patient Phase 2 clinical trial – BOSTON, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. Today the Company announced the presentation of clinical and preclinical data in support of its expanding Duchenne clinical franchise at the 29th Annual Congress of the World Muscle Society in Prague, Czechia from October 8-12, 2024.
Neutral
GlobeNewsWire
3 months ago
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines. Today, the Company announced that Natarajan Sethuraman, PhD, currently its Chief Scientific Officer, has been promoted to President of Research and Development, effective immediately.
Neutral
Business Wire
3 months ago
āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors
BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA). “Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical.
Neutral
GlobeNewsWire
3 months ago
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of World Duchenne Awareness Day, grants are designed to fund efforts advancing diversity, equity, inclusion and accessibility within the Duchenne community - BOSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible.
Positive
Zacks Investment Research
4 months ago
Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to loss of $0.78 per share a year ago.
Charts implemented using Lightweight Charts™